tiprankstipranks
Is TVTX a Buy, Before Earnings?
PremiumPre-EarningsIs TVTX a Buy, Before Earnings?
4d ago
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Premium
The Fly
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
8d ago
Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS
Premium
Ratings
Travere Therapeutics: Strong Buy Rating Driven by Filspari’s $1 Billion Market Potential in FSGS
9d ago
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
PremiumThe FlyTravere Therapeutics to submit sNDA for FILSPARI in FSGS
11d ago
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
Premium
Ratings
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
19d ago
Travere Therapeutics price target raised to $24 from $20 at TD Cowen
Premium
The Fly
Travere Therapeutics price target raised to $24 from $20 at TD Cowen
23d ago
MHRA approves Travere’s sparsentan to treat adults with primary IgAN
PremiumThe FlyMHRA approves Travere’s sparsentan to treat adults with primary IgAN
3M ago
Travere Therapeutics price target raised to $22 from $12 at Piper Sandler
Premium
The Fly
Travere Therapeutics price target raised to $22 from $12 at Piper Sandler
3M ago
Travere Therapeutics 7.81M share Spot Secondary priced at $16.00
Premium
The Fly
Travere Therapeutics 7.81M share Spot Secondary priced at $16.00
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100